

VULVOVAGINAL CANDIDIASIS: A REAL-WORLD EVIDENCE STUDY OF THE PERCEIVED BENEFITS OF CANESTEN®

L. Zhang, R. De Salvo, A. Ehret, K. Young and S. Trapp

Objectives

Real-world evidence study, aimed to provide **consumer important information on the benefits of Canesten** (clotrimazole/fluconazole-based product) in the treatment of vulvovaginal candidiasis (VVC). The focus of the outcome is:

- > Symptom Improvement and Relief.
- > Speed of Onset.
- > Quality of Life (QoL).
- Product Attributes and Satisfaction.

Study design



Retrospective observational study.



Web based interviews.

Population



Women who have used a Canesten product for **VVC** within last 6 months.

N=475. (UK=262 and Canada=213).



Age group

31%

37%

32%

18-30 31-40

41-60

Results

45% Experienced both internal and external symptoms.



Of women stated that Canesten products have improved their quality of life.



Of women agree that Canesten products have improved their symptoms.



Of women who would use Canesten again if they had VYI.



Reported that Canesten products were easy or very easy to use.



Speed of Symptomatic Relief



Within 4 hours.



Agreed that the product start to work from the first application.



Within 1 day.



Of women that have tested both vaginal tablet alone and combi product (int + ext) claimed that **combi pack provides faster relief.**

Discussion

V

Canesten products not only alleviate symptoms effectively but also enhance QoL.

Canesten products provide **rapid onset of relief**, particularly with topical treatments.

Women experiencing both internal and external symptoms reported Canesten combi pack (vaginal & external products) to provide faster relief of symptoms than single product treatments.

Conclusion

The real-world evidence supports **Canesten's effectiveness** in providing rapid relief from **VVC symptoms**, significantly **improving QoL** and achieving **high consumer satisfaction**. Despite the study's limitations, we consider our findings to be robust and to add supplementary value to the information obtained from randomized trials of VVC therapies. These insights are crucial for guiding consumer choices regarding treatment options.

Additional Information: This is an infographic summary of the original research article published in SAGE Open Medicine: Zhang L, De Salvo R, Ehret A, Young K, Trapp S. Vulvovaginal candidiasis: A real-world evidence study of the perceived benefits of Canesten®. SAGE Open Med. 2022 Mar 28;10:20503121221085437. doi: 10.1177/20503121221085437. PMID: 35371482; PMCID: PMC8969009. The study was fully funded by Bayer Consumer Care AG, Basel, Switzerland. CH-20250911-58